<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122182</url>
  </required_header>
  <id_info>
    <org_study_id>CTC0312</org_study_id>
    <nct_id>NCT05122182</nct_id>
  </id_info>
  <brief_title>Controlled Trial of Angiotensin Receptor Blocker (ARB) &amp; Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19</brief_title>
  <acronym>CLARITY 2</acronym>
  <official_title>An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) &amp; Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The George Institute for Global Health, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLARITY 2.0 is an investigator-initiated trial that will evaluate the safety and efficacy of&#xD;
      dual treatment with repagermanium, a CCR2 antagonist, and candesartan, an ARB, in patients&#xD;
      hospitalised with COVID-19 disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 17, 2021</start_date>
  <completion_date type="Anticipated">December 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Health Score at day 14</measure>
    <time_frame>14 days</time_frame>
    <description>The primary objective is to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by the Clinical Health Score at day 14, which is determined within an 8-point ordinal scale of health status:&#xD;
Not hospitalised, no limitations on activities.&#xD;
Not hospitalised, limitation on activities.&#xD;
Hospitalised, not requiring supplemental oxygen.&#xD;
Hospitalised, requiring supplemental oxygen by mask or nasal prongs.&#xD;
Hospitalised, on non-invasive ventilation or high-flow oxygen devices.&#xD;
Hospitalised, requiring intubation and mechanical ventilation.&#xD;
Hospitalised, on invasive mechanical ventilation and additional organ support (ECMO).&#xD;
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Health Score at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>The primary objective is to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by the Clinical Health Score at day 28, which is determined within an 8-point ordinal scale of health status:&#xD;
Not hospitalised, no limitations on activities.&#xD;
Not hospitalised, limitation on activities.&#xD;
Hospitalised, not requiring supplemental oxygen.&#xD;
Hospitalised, requiring supplemental oxygen by mask or nasal prongs.&#xD;
Hospitalised, on non-invasive ventilation or high-flow oxygen devices.&#xD;
Hospitalised, requiring intubation and mechanical ventilation.&#xD;
Hospitalised, on invasive mechanical ventilation and additional organ support (ECMO).&#xD;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by incidence of ICU admission in days 0-28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by incidence of deaths in days 0-28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed from hospital admission to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by incidence of acute kidney injury in days 0-28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Failure</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by incidence of respiratory failure in days 0-28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital admission</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by days of inpatient stay from admission to discharge or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU Admission</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by days in ICU from admission to transfer to ward or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of ventilatory support</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by count of days with ventilation in days 0-28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of dialysis</measure>
    <time_frame>28 days</time_frame>
    <description>The secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by count of days with dialysis in days 0-28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Health Score at day 60</measure>
    <time_frame>60 days</time_frame>
    <description>The primary objective is to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by the Clinical Health Score at day 60, which is determined within an 8-point ordinal scale of health status:&#xD;
Not hospitalised, no limitations on activities.&#xD;
Not hospitalised, limitation on activities.&#xD;
Hospitalised, not requiring supplemental oxygen.&#xD;
Hospitalised, requiring supplemental oxygen by mask or nasal prongs.&#xD;
Hospitalised, on non-invasive ventilation or high-flow oxygen devices.&#xD;
Hospitalised, requiring intubation and mechanical ventilation.&#xD;
Hospitalised, on invasive mechanical ventilation and additional organ support (ECMO).&#xD;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Health Score at day 90</measure>
    <time_frame>90 days</time_frame>
    <description>The primary objective is to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by the Clinical Health Score at day 90, which is determined within an 8-point ordinal scale of health status:&#xD;
Not hospitalised, no limitations on activities.&#xD;
Not hospitalised, limitation on activities.&#xD;
Hospitalised, not requiring supplemental oxygen.&#xD;
Hospitalised, requiring supplemental oxygen by mask or nasal prongs.&#xD;
Hospitalised, on non-invasive ventilation or high-flow oxygen devices.&#xD;
Hospitalised, requiring intubation and mechanical ventilation.&#xD;
Hospitalised, on invasive mechanical ventilation and additional organ support (ECMO).&#xD;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Health Score at day 180</measure>
    <time_frame>180 days</time_frame>
    <description>The primary objective is to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by the Clinical Health Score at day 180, which is determined within an 8-point ordinal scale of health status:&#xD;
Not hospitalised, no limitations on activities.&#xD;
Not hospitalised, limitation on activities.&#xD;
Hospitalised, not requiring supplemental oxygen.&#xD;
Hospitalised, requiring supplemental oxygen by mask or nasal prongs.&#xD;
Hospitalised, on non-invasive ventilation or high-flow oxygen devices.&#xD;
Hospitalised, requiring intubation and mechanical ventilation.&#xD;
Hospitalised, on invasive mechanical ventilation and additional organ support (ECMO).&#xD;
Death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Hypotension</measure>
    <time_frame>28 days</time_frame>
    <description>The specific safety objectives are to evaluate the safety of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by incidence of hypotension in days 0-28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Hyperkalemia</measure>
    <time_frame>28 days</time_frame>
    <description>The specific safety objectives are to evaluate the safety of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by incidence of hyperkalemia in days 0-28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Deranged Liver Function Tests</measure>
    <time_frame>28 days</time_frame>
    <description>The specific safety objectives are to evaluate the safety of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by incidence of deranged liver function tests in days 0-28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Serious Adverse Events (SAEs)</measure>
    <time_frame>28 days</time_frame>
    <description>The specific safety objectives are to evaluate the safety of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by total number of SAEs in days 0-28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hospital readmission</measure>
    <time_frame>90 days</time_frame>
    <description>Admission for overnight stay up to day 90 following initial hospital discharge.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>Interventional Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + fixed dose repagermanium one x 120mg immediate release capsule twice daily (total daily dose 240mg). Treatment will continue for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm #1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm #2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Titratable matched placebo candesartan one tablet twice daily + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>Angiotensin Receptor Blocker (ARB)</description>
    <arm_group_label>Control Arm #1</arm_group_label>
    <arm_group_label>Interventional Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repagermanium</intervention_name>
    <description>C-C chemokine receptor type 2 (CCR2) antagonist</description>
    <arm_group_label>Interventional Arm</arm_group_label>
    <other_name>DMX-200</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Placebo</intervention_name>
    <description>Angiotensin Receptor Blocker (ARB) placebo</description>
    <arm_group_label>Control Arm #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repagermanium Placebo</intervention_name>
    <description>C-C chemokine receptor type 2 (CCR2) antagonist placebo</description>
    <arm_group_label>Control Arm #1</arm_group_label>
    <arm_group_label>Control Arm #2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged ≥ 18 years (maximum 65 years old in India).&#xD;
&#xD;
          2. Laboratory-confirmed diagnosis of SARS-CoV-2 infection within 10 days prior to&#xD;
             randomisation. (Confirmation must be through Reverse Transcription Polymerase Chain&#xD;
             Reaction [RT-PCR] method)&#xD;
&#xD;
          3. Intended for hospital admission for management of COVID-19.&#xD;
&#xD;
          4. Patients with moderate (respiratory rate of ≥ 24/minute or SPO2: 90% to ≤ 93% on room&#xD;
             air) or severe (respiratory rate of ≥ 30/minute or SPO2: &lt;90% on room air) COVID-19.&#xD;
&#xD;
          5. Systolic Blood Pressure (SBP) ≥ 120 mmHg OR SBP ≥ 115 mmHg and currently treated with&#xD;
             a non-RAASi BP lowering agent that can be ceased.&#xD;
&#xD;
          6. Willing and able to comply with all study requirements, including treatment, timing&#xD;
             and/or nature of required assessments.&#xD;
&#xD;
          7. Documented informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently treated with an ACEi, ARB or aldosterone antagonist, aliskiren, or ARNi&#xD;
&#xD;
          2. Intolerance of ARBs&#xD;
&#xD;
          3. Serum potassium &gt;5.5 mmol/L&#xD;
&#xD;
          4. An estimated Glomerular Filtration Rate (eGFR) &lt;30ml/min/1.732m&#xD;
&#xD;
          5. Known biliary obstruction, known severe hepatic impairment (Child-Pugh-Turcotte score&#xD;
             10-15)&#xD;
&#xD;
          6. Pregnancy, lactation, or inadequate contraception.&#xD;
&#xD;
          7. Participation in a study of a novel investigational product within 28 days prior to&#xD;
             randomisation.&#xD;
&#xD;
          8. Plans to participate in another study of a novel investigational product during this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meg Jardine</last_name>
    <role>Study Chair</role>
    <affiliation>NHMRC Clinical Trials Centre, The University of Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivekanand Jha</last_name>
    <role>Study Chair</role>
    <affiliation>The George Institute for Global Health, India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrina Diamante</last_name>
    <phone>+612 9562 5000</phone>
    <email>Clarity2.study@sydney.edu.au</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV2</keyword>
  <keyword>Angiotensin Receptor Blocker (ARB)</keyword>
  <keyword>C-C chemokine receptor type 2 (CCR2) antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proxigermanium</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

